Project Details
Projekt Print View

SFB 1118:  Reactive metabolites as a cause of diabetes complications

Subject Area Medicine
Biology
Chemistry
Term from 2014 to 2023
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 236360313
 
According to current figures, one in ten adults has diabetes and an equally large number has the precursor to it, prediabetes. Diabetes is the leading cause of blindness, chronic kidney failure, heart attack, stroke and leg amputations. These diabetic complications often determine the mortality of patients with diabetes. Diabetic complications are evident in subtypes of diabetes as early as the manifestation of the disease itself. However, no therapeutic approaches are currently available that specifically target intracellular metabolic pathways underlying the development of diabetic complications. In addition, it is still not possible to reliably determine the risk of late onset diabetes or to induce remission of established late complications.The SFB1118 aims to understand diabetes complications by studying the intracellular effects of reactive metabolites (RM), such as reactive oxygen species (ROS), dicarbonyls (DC), or glucose metabolites (O-Glc-NAc), which are generated during energy metabolism.Work in the first funding periods identified novel molecular pathomechanisms of diabetic complications as well as specific targets of RM in the development of insulin resistance, retinopathy, sensory and autonomic neuropathy, nephropathy, and diabetic cardiopathy. Paradigm-shifting findings of this SFB demonstrated that synergistic enzyme systems and autoregulatory feedback loops determine the accumulation of RM. RM induce post-translational modifications of proteins and DNA with functional changes that are followed by cellular compensatory mechanisms, insulin resistance, DNA damage and/or senescence and can lead to tissue fibrosis and organ failure (multiple-hit concept).The aim of the 3rd funding period is to test the causality and reversibility of the newly identified mechanisms underlying the complications, by utilizing targeted interventions in different animal models and to transfer the new findings to the clinic. The SFB will test whether, and in which subtypes of diabetes these mechanisms are relevant for the development of diabetes complications and which biomarkers indicate them. The new molecular mechanisms will be translated into clinical stages according to the progression of diabetic damage, which will help validate intervention options and better define subgroups of patients.Our ultimate goal is to achieve long-term targets for prevention and remission of existing late complications in diabetes.
DFG Programme Collaborative Research Centres

Completed projects

Participating University Universität Leipzig
Spokespersons Professor Dr. Stephan Herzig, from 9/2021 until 6/2022; Professor Dr. Peter Nawroth, until 8/2021; Professorin Dr. Julia Szendrödi, since 7/2022
 
 

Additional Information

Textvergrößerung und Kontrastanpassung